Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
Latest Information Update: 01 Jan 2025
Price :
$35 *
At a glance
- Drugs Ecubectedin (Primary) ; Irinotecan (Primary) ; Granulocyte colony-stimulating factors
- Indications Adenocarcinoma; Adrenocortical carcinoma; Biliary cancer; Bladder cancer; Breast cancer; Carcinoma; Cervical cancer; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Gastric cancer; Leiomyosarcoma; Liposarcoma; Liver cancer; Malignant-mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors PharmaMar
- 08 Jun 2021 Results (n=37) assessing safety, efficacy and pharmacokinetics of PM14 in patients with advanced solid tumors, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 22 Sep 2017 New trial record